On the other hand, immune checkpoint-blocking antibodies such as anti-PD-1 and anti-PD-L1 agents, approved for treatment of immunogenic tumors such as melanoma, classic Hodgkin lymphoma, and others, act by unleashing the cytotoxic T-cell activity because they deblock the inhibitory binding of the PD-L1 on tumor cells to the PD-1 immune checkpoint T-cell receptors. The gene discussed is CD274; the disease is Hodgkins lymphoma.